Abstract
Silymarin is a complex mixture of four flavonolignan isomers (silybin, isosilybin, silydianin and silychristin) obtained from ‘milk thistle’ (Silybum marianum). This plant compound is used almost exclusively for hepatoprotection. Because of its low and poor oral bioavailability, silymarin was formulated as a nanoemulsion to increase its solubility (and so its oral bioavailability) as well as therapeutic activity. The present study assessed the hepatoprotective activity on Wistar rats by determining biochemical parameters and histopathological properties of the nanoemulsion formulation of silymarin against carbon tetrachloride (CCl4)-induced hepatotoxicity. Hepatoprotective activity was evaluated by the activity of serum alkaline phosphatase, alanine transaminase and aspartate transaminase; antioxidative defence markers (concentration of reduced glutathione); oxidative stress parameter (thiobarbituric acid reactive substances) and liver histopathology. The nanoemulsion-treated group showed significant decreases in glutamate oxaloacetate transaminase, pyruvate transaminase, alkaline phosphotase, total bilirubin and tissue lipid peroxides and increased total protein, albumin, globulin and tissue glutathione as compared to toxicant. The results indicate an excellent potential of the nanoemulsion formulation for the reversal of CCl4-induced liver toxicity in rats as compared to standard silymarin.
This is a preview of subscription content, access via your institution.
References
Attama, A. A., Nzekwe, I. T., Nnamani, P. O., Adikwu, M. U., and Onugu, C. O., The use of solid self-emulsifying systems in the delivery of diclofenac. Int. J. Pharm., 262, 23–28 (2003).
Barbarino, F., Neumann, E., Deaciuc, I., Ghelberg, N. W., Suciu, A., Cotutiu, C., Racovitǎa, L., Stroilǎa, C., Nagy, S., Pǎarǎau, N., Toader, S., and Brilinschi, C., Effect of silymarin on experimental liver lesions. Med. Interne, 19, 347–357 (1981).
Bessey, O. A., Lowry, O. H., and Brock, M. J., A method for the rapid determination of alkaline phosphates with five cubic millimeters of serum. J. Biol. Chem., 164, 321–329 (1964).
Comoglio, A., Tomasi, A., Malandrino, S., Poli, G., and Albano, E., Scavenging effect of silipide, a new silybinphospholipid complex, on ethanol-derived free radicals. Biochem. Pharmacol., 50, 1313–1316 (1995).
Comporti, M., Maellaro, E., Del Bello, B., and Casini, A. F., Glutathione depletion: its effects on other antioxidant systems and hepatocellular damage. Xenobiotica, 21, 1067–1076 (1991).
Constantinides, P. P., Lipid microemulsions for improving drug dissolution and oral absorption: physical and biopharmaceutical aspects. Pharm. Res., 12, 1561–1572 (1995).
Davila, J. C., Lenherr, A., and Acosta, D., Protective effect of flavonoids on drug-induced hepatotoxicity in vitro. Toxicology, 57, 267–286 (1989).
Desplaces, A., Choppin, J., Vogel, G., and Trost, W., The effects of silymarin on experimental phalloidine poisoning. Arzneimittelforschung, 25, 89–96 (1975).
Ellman, G. L., Tissue sulfhydryl groups. Arch. Biochem. Biophys., 82, 70–77 (1959).
Fang, Y. Z., Yang, S., and Wu, G., Free radicals, antioxidants, and nutrition. Nutrition, 18, 872–879 (2002).
Floersheim, G. L., Eberhard, M., Tschumi, P., and Duckert, F., Effects of penicillin and silymarin on liver enzymes and blood clotting factors in dogs given a boiled preparation of Amanita phalloides. Toxicol. Appl. Pharmacol., 46, 455–462 (1978).
Flora, K., Hahn, M., Rosen, H., and Benner, K., Milk thistle (Silybum marianum) for the therapy of liver disease. Am. J. Gastroenterol., 93, 139–143 (1998).
Gadetta, V., Bombardelli, E., and Pifferi, G., Complexes of flavanolignans with phospholipids, preparations thereof and associated pharmaceutical compositions. U. S. Patent, 4764508 (1988).
Galighter, A. E. and Koyloff, E. N., Essential of Practical Microtechnique, Lea and Febiger, Philadelphia, (1971).
Giacomelli, S., Gallo, D., Apollonio, P., Ferlini, C., Distefano, M., Morazzoni, P., Riva, A., Bombardelli, E., Mancuso, S., and Scambia, G., Silybin and its bioavailable phospholipid complex (IdB1016) potentiate in vitro and in vivo activity of cisplatin. Life Sci., 70, 1447–1459 (2002).
Hall, P. D., Plummer, J. L., Ilsley, A. H., and Cousins, M. J., Hepatic fibrosis and cirrhosis after chronic administration of alcohol and “low-dose” carbon tetrachloride vapor in the rat. Hepatology, 13, 815–819 (1991).
Javed, S., Kohli, K., and Ali, M., Patented bioavailability enhancement techniques of silymarin. Recent Pat. Drug Deliv. Formul., 4, 145–152 (2010).
Johnston, D. E. and Kroening, C., Mechanism of early carbon tetrachloride toxicity in cultured rat hepatocytes. Pharmacol. Toxicol., 83, 231–239 (1998).
Kaplowitz N., Aw, T. Y., Simon, F. R., and Stolz, A., Druginduced hepatotoxicity. Ann. Intern. Med., 104, 826–839 (1986).
Khandavilli, S. and Panchagnula, R., Nanoemulsions as versatile formulations for paclitaxel delivery: peroral and dermal delivery studies in rats. J. Invest. Dermatol., 127, 154–162 (2007).
Kingsley, S. R. and Frankel, S. J., The determination of serum total protein albumin and globulin by the biuret reaction. J. Biol. Chem., 128, 131–137 (1939).
Kogan, A., Aserin, A., and Garti, N., Improved solubilization of carbamazepine and structural transitions in nonionic microemulsions upon aqueous phase dilution. J. Colloid Interface Sci., 315, 637–647 (2007).
Kosina, P., Kren, V., Gebhardt, R., Grambal, F., Ulrichová, J., and Walterová, D., Antioxidant properties of silybin glycosides. Phytother. Res., 16, S33–S39 (2002).
Lauterburg, B. H., Analgesics and glutathione. Am. J. Ther., 9, 225–233 (2002).
Lawrence, M. J. and Rees, G. D., Microemulsion-based media as novel drug delivery systems. Adv. Drug Deliv. Rev., 45, 89–121 (2000).
Lee, M. H., Lin, H. Y., Chen, H. C., and Thomas, J. L., Ultrasound mediates the release of curcumin from microemulsions. Langmuir, 4, 1707–1713 (2008).
Madaus, R., Halbach, G., and Trost, W., Salt of silymarin group with aminopolyhydroxy alcohols. U. S. Patent, 3994925 (1976).
Mallory, H. T. and Evelyn, K. A., The determination of bilirubin with photoelectric colorimeter. J. Biol. Chem., 119, 481–490 (1937).
Mereish, K. A., Bunner, D. L., Ragland, D. R., and Creasia, D. A., Protection against microcystin-LR-induced hepatotoxicity by silymarin: biochemistry, histopathology, and lethality. Pharm. Res., 8, 273–277 (1991).
Morazzoni, P. and Bombardelli, E., Silybum marianum (Carduus marianus) Fitoterapia, 66, 3–42 (1994).
Muriel, P. and Mourelle, M., Prevention by silymarin of membrane alterations in acute CCl4 liver damage. J. Appl. Toxicol., 10, 275–279 (1990).
Muriel, P., Garciapiña, T., Perez-Alvarez, V., and Mourelle, M., Silymarin protects against paracetamol-induced lipid peroxidation and liver damage. J. Appl. Toxicol., 12, 439–442 (1992).
Najafzadeh, H., Jalali, M. R., Morovvati, H., and Taravati, F., Comparison of the prophylactic effect of silymarin and deferoxamine on iron overload-induced hepatotoxicity in rat. J. Med. Toxicol., 6, 22–26 (2010).
Pepping, J., Milk thistle: Silybum marianum. Am. J. Health Syst. Pharm., 56, 1195–1197 (1999).
Polyak, S. J., Morishima, C., Lohmann, V., Pal, S., Lee, D. Y., Liu, Y., Graf, T. N., and Oberlies, N. H., Identification of hepatoprotective flavonolignans from silymarin. Proc. Natl. Acad. Sci. U. S. A., 107, 5995–5999 (2010).
Porter, W. R. and Neal, R. A., Metabolism of thioacetamide and thioacetamide S-oxide by rat liver microsomes. Drug Metab. Dispos., 6, 379–388 (1978).
Pouton, C. W. and Porter, C. J. H., Formulation of lipidbased delivery systems for oral administration: materials, methods and strategies. Adv. Drug Deliv. Rev., 60, 625–637 (2008).
Pradhan, S. C. and Girish, C., Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Indian J. Med. Res., 124, 491–504 (2006).
Rainone, F., Milk thistle. Am. Fam. Physician, 72, 1285–1288 (2005).
Recknagel, R. O., Glende, E. A. Jr., Dolak, J. A., and Waller, R. L., Mechanisms of carbon tetrachloride toxicity. Pharmacol. Ther., 43, 134–154 (1989).
Reitman, S. and Frankel, S., A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. Am. J. Clin. Pathol., 28, 56–63 (1957).
Schriewer, H. and Weinhold, F., The influence of silybin from Silybum marianum (L.) Gaertn. on in vitro phosphatidyl choline biosynthesis in rat livers. Arzneimittelforschung, 29, 791–792 (1979).
Sedlak, J. and Lindsay, R. H., Estimation of total, proteinbound, and nonprotein sulfhydryl groups in tissue with Ellman’s reagent. Anal. Biochem., 25, 192–205 (1968).
Siegers, C. P., Frühling, A., and Younes, M., Influence of dithiocarb, (+)-catechin and silybine on halothane hepatotoxicity in the hypoxic rat model. Acta Pharmacol. Toxicol. (Copenh), 53, 125–129 (1983).
Srivastava, S. P., Chen, N. Q., and Holtzman, J. L., The in vitro NADPH-dependent inhibition by CCl4 of the ATPdependent calcium uptake of hepatic microsomes from male rats. Studies on the mechanism of the inactivation of the hepatic microsomal calcium pump by the CCl3 radical. J. Biol. Chem., 265, 8392–8399 (1990).
Thakur, S. K., Silymarin-A hepatoprotective agent. Gastroenterol. Today, 6, 78–82 (2002).
Tiwari, S. B. and Amiji, M. M., Improved oral delivery of paclitaxel following administration in nanoemulsion formulations. J. Nanosci. Nanotechnol., 6, 3215–3221 (2006).
Valenzuela, A., Guerra, R., and Garrido, A., Silybin dihemisuccinate protects rat erythrocytes against phenylhydrazine-induced lipid peroxidation and hemolysis. Planta Med., 53, 402–405 (1987).
Vyas, T. K., Shahiwala,, A., and Amiji M. M., Improved oral bioavailability and brain transport of Saquinavir upon administration in novel nanoemulsion formulations. Int. J. Pharm., 347, 93–101 (2008).
Wachter, W. and Zaeske, H., Process for the manufacture of flavanolignan preparation with improve release and absorbability, compositions obtainable thereby and their use for the preparation of pharmaceuticals. U. S. Patent, 6020384 (2000).
Wang, M., Grange, L. L., and Tao, J., Hepatoprotective properties of Silybum marianum herbal formulation on ethanol-induced liver damage. Fitoterapia, 67, 167–171 (1996).
Woo, J. S., Kim, T. S., Park, J. H., and Chi, S. C., Formulation and biopharmaceutical evaluation of silymarin using SMEDDS. Arch. Pharm. Res., 30, 82–89 (2007).
Wu, W., Wang, Y., and Que, L., Enhanced bioavailability of silymarin by self-microemulsifying drug delivery system. Eur. J. Pharm. Biopharm., 63, 288–294 (2006).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Parveen, R., Baboota, S., Ali, J. et al. Effects of silymarin nanoemulsion against carbon tetrachloride-induced hepatic damage. Arch. Pharm. Res. 34, 767–774 (2011). https://doi.org/10.1007/s12272-011-0510-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-011-0510-8
Key words
- Silymarin
- Nanoemulsion
- Carbon tetrachloride
- Hepatic damage